Compare · PEPG vs WVE

PEPG vs WVE

Side-by-side comparison of PepGen Inc. (PEPG) and Wave Life Sciences Inc. (WVE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PEPG and WVE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • WVE is the larger of the two at $536.5M, about 1.4x PEPG ($370.4M).
  • PEPG has been more active in the news (12 items in the past 4 weeks vs 6 for WVE).
  • WVE has more recent analyst coverage (24 ratings vs 6 for PEPG).
MetricPEPGWVE
Company
PepGen Inc.
Wave Life Sciences Inc.
Price
-
-
Market cap
$370.4M
$536.5M
1M return
-
-19.38%
1Y return
-
-59.66%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2022
2015
News (4w)
12
6
Recent ratings
6
24
PEPG

PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

WVE

Wave Life Sciences Inc.

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Latest PEPG

Latest WVE